Pacira Reports First Quarter EXPAREL Revenues Of $56.0 Million And First Quarter 2015 Financial Results

PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2015.

Help employers find you! Check out all the jobs and post your resume.